# Ernexa Therapeutics Inc. (ERNA)

Source: https://www.quantisnow.com/company/ERNA
Generated: 2026-11-15T02:14:08.839Z

- Ticker: ERNA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0000748592

## Latest ERNA news and filings

- 2026-11-10 21:59 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Ernexa Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-ernexa-therapeutics-inc-6784563)
- 2026-11-06 21:50 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Ernexa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-ernexa-therapeutics-inc-6779397)
- 2026-10-22 12:53 UTC [Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment](https://www.quantisnow.com/insight/ernexa-therapeutics-highlights-erna-101s-path-toward-the-clinic-and-differentiated-6754606)
- 2026-10-15 21:25 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ernexa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ernexa-therapeutics-inc-6748379)
- 2026-10-12 20:05 UTC [Conference Announcement] [Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series](https://www.quantisnow.com/insight/ernexa-therapeutics-to-participate-in-virtual-investor-closing-bell-series-6743717)
- 2026-10-06 12:55 UTC [Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center](https://www.quantisnow.com/insight/ernexa-therapeutics-erna-101-selected-for-flash-talk-presentation-at-nature-6738412)
- 2026-10-01 13:20 UTC [Leadership Update] [Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic](https://www.quantisnow.com/insight/ernexa-therapeutics-ceo-corner-highlights-appointment-of-dr-robert-j-6731821)
- 2026-09-30 12:32 UTC [Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND](https://www.quantisnow.com/insight/ernexa-therapeutics-reports-compelling-erna-101-safety-results-across-three-critical-6730116)
- 2026-09-29 13:15 UTC [Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy](https://www.quantisnow.com/insight/ernexa-therapeutics-selected-for-emerging-track-at-2026-cell-gene-6728837)
- 2026-09-22 20:13 UTC [SEC Form 3] [SEC Form 3 filed by new insider Spiegel Robert J.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-spiegel-robert-j-6722996)
- 2026-09-17 12:42 UTC [Leadership Update] [Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors](https://www.quantisnow.com/insight/ernexa-therapeutics-appoints-accomplished-biopharmaceutical-executive-robert-j-spiegel-md-6718592)
- 2026-09-16 21:30 UTC [SEC Form 8-K] [Ernexa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/ernexa-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6717993)
- 2026-09-16 20:50 UTC [SEC Form 8-K] [Ernexa Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/ernexa-therapeutics-inc-filed-sec-form-8-k-leadership-update-6717815)
- 2026-09-15 12:42 UTC [Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing](https://www.quantisnow.com/insight/ernexa-therapeutics-reports-positive-disease-modifying-erna-201-preclinical-data-reinforcing-6715541)
- 2026-09-14 13:05 UTC [Conference Announcement] [Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/ernexa-therapeutics-to-present-at-the-hc-wainwright-28th-annual-6714010)
- 2026-09-02 01:59 UTC [SEC Form 4] [SEC Form 4 filed by Director Bristol James Arthur](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bristol-james-arthur-6702064)
- 2026-09-02 01:56 UTC [SEC Form 4] [SEC Form 4 filed by Director Cicala Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cicala-peter-6702063)
- 2026-09-02 01:48 UTC [SEC Form 4] [SEC Form 4 filed by Director Wexler William A.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wexler-william-a-6702061)
- 2026-09-02 01:49 UTC [SEC Form 4] [SEC Form 4 filed by Director Polinsky David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-polinsky-david-6702060)
- 2026-09-02 01:47 UTC [SEC Form 4] [SEC Form 4 filed by Director Ratner Elena](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ratner-elena-6702059)
- 2026-09-02 01:46 UTC [SEC Form 4] [SEC Form 4 filed by President and CEO Luther Sanjeev](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-and-ceo-luther-sanjeev-6702058)
- 2026-08-27 23:52 UTC [SEC Form 3] [New insider Polinsky David claimed ownership of 8,000 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-polinsky-david-claimed-ownership-of-8000-shares-sec-6697692)
- 2026-08-27 13:01 UTC [Market Insight] [JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs](https://www.quantisnow.com/insight/jtc-team-releases-virtual-investor-why-now-on-demand-conference-featuring-6696641)
- 2026-08-27 13:01 UTC [Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference](https://www.quantisnow.com/insight/ernexa-therapeutics-participates-in-the-virtual-investor-why-now-on-demand-6696637)
- 2026-08-10 13:01 UTC [Leadership Update] [Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage](https://www.quantisnow.com/insight/ernexa-therapeutics-strengthens-board-with-veteran-biotech-executive-david-polinsky-6673059)
- 2026-08-06 21:31 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Ernexa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-ernexa-therapeutics-inc-6670098)
- 2026-07-24 13:20 UTC [Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies](https://www.quantisnow.com/insight/ernexa-therapeutics-ceo-corner-emphasizes-how-erna-101-could-help-unlock-6648062)
- 2026-07-15 14:42 UTC [Three Biotechs Deliver Catalysts to Watch](https://www.quantisnow.com/insight/three-biotechs-deliver-catalysts-to-watch-6637983)
- 2026-07-15 11:50 UTC [Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry](https://www.quantisnow.com/insight/ernexa-therapeutics-receives-independent-validation-of-erna-101-with-complete-tumor-6637585)
- 2026-07-14 13:01 UTC [Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026](https://www.quantisnow.com/insight/ernexa-therapeutics-ceo-corner-highlights-differentiated-erna-101-platform-as-company-6636299)
- 2026-07-02 20:40 UTC [SEC Form 8-K] [Ernexa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/ernexa-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6626019)
- 2026-07-02 20:30 UTC [SEC Form 8-K] [Ernexa Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ernexa-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6625789)
- 2026-06-26 20:30 UTC [SEC Form 8-K] [Ernexa Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ernexa-therapeutics-inc-filed-sec-form-8-k-leadership-update-financial-6617522)
- 2026-06-25 13:15 UTC [Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients](https://www.quantisnow.com/insight/ernexa-therapeutics-launches-ceo-corner-to-provide-deeper-insights-into-6615403)
- 2026-06-17 12:47 UTC [Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study](https://www.quantisnow.com/insight/ernexa-therapeutics-positioned-to-become-a-clinical-stage-biotechnology-company-as-6606034)
- 2026-06-09 12:41 UTC [Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer](https://www.quantisnow.com/insight/ernexa-therapeutics-highlights-ovarian-cancer-unmet-need-hope-for-patients-6594734)
- 2026-05-27 12:11 UTC [Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development](https://www.quantisnow.com/insight/ernexa-therapeutics-successfully-completes-key-manufacturing-and-ind-preparation-milestones-6573946)
- 2026-05-20 12:31 UTC [Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity](https://www.quantisnow.com/insight/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-6564475)
- 2026-05-16 00:54 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Ernexa Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-ernexa-therapeutics-inc-6558814)
- 2026-05-11 21:12 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Ernexa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-ernexa-therapeutics-inc-6545814)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ERNA
- Earnings history: https://www.quantisnow.com/earnings/ERNA
- Dividend history: https://www.quantisnow.com/dividends/ERNA
- Insider transactions: https://www.quantisnow.com/insiders/ERNA
- Options chain: https://www.quantisnow.com/options/ERNA
- SEC 8-K filings only: https://www.quantisnow.com/company/ERNA/8-k
- RSS and alerts for ERNA: https://www.quantisnow.com/docs/rss-feeds.md